Experienced in Juvenile Temporal Arteritis

Maud D'aveni

Vandoeuvre-les-nancy, FR 
Experienced in Juvenile Temporal Arteritis
Vandoeuvre-les-nancy, FR 
OverviewLocationsClinical Research

Overview

Maud D'aveni practices in Vandoeuvre-les-nancy, France. Ms. D'aveni is rated as an Experienced expert by MediFind in the treatment of Juvenile Temporal Arteritis. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Graft Versus Host Disease (GvHD), Paroxysmal Cold Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 47 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Juvenile Temporal Arteritis.

Gender
Female

Locations

Vandoeuvre-les-nancy, 54500, France
Other Locations
Nancy, France
Bordeaux, France
Paris, 75015, France
CH Cornouaille
Quimper, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Prospective Study GFM-DACORAL-DLI ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
A Phase II Prospective Study GFM-DACORAL-DLI ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Enrollment Status: Completed
Publish Date: May 14, 2025
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Other
Study Phase: Not Applicable
View 2 Less Clinical Trials

47 Total Publications

Optimized GMP-grade Wharton's jelly's mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention.
Optimized GMP-grade Wharton's jelly's mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention.
Journal: Current research in translational medicine
Published: May 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. D'aveni's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile